Interim results from a phase I study of lumiliximab (IDEC-152, Anti-CD23 antibody) therapy for relapsed or refractory CLL Meeting Abstract
| Authors: | Byrd, J. C.; O'Brien, S.; Flinn, I.; Kipps, T. J.; Weiss, M. A.; Reid, J.; Wynne, D.; Leigh, B. R. |
| Abstract Title: | Interim results from a phase I study of lumiliximab (IDEC-152, Anti-CD23 antibody) therapy for relapsed or refractory CLL |
| Meeting Title: | 45th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 102 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2003 Dec 6-9 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2003-11-01 |
| Start Page: | 74A |
| Language: | English |
| ACCESSION: | WOS:000186536700248 |
| PROVIDER: | wos |
| PUBMED: | 14650391 |
| Notes: | Meeting Abstract: 248 -- 45th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2003 -- SAN DIEGO, CALIFORNIA -- 1 -- Source: Wos |
